射频消融作为桥梁治疗肝移植的肝细胞癌：十年期治疗分析

StephenW

Hepatobiliary Malignancies
Radiofrequency Ablation of Hepatocellular Carcinoma as Bridge Therapy to Liver Transplantation: A Ten Year Intention-to-treat Analysis
Authors

    Accepted manuscript online: 7 February 2017Full publication history
    DOI: 10.1002/hep.29098View/save citation
    Cited by: 0 articles

ABSTRACT

In a long-term (10 years) study of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) as bridging therapy in patients listed for orthotopic liver transplantation (LT), we evaluated the impact of RFA on waiting list dropout rate, post-LT tumor recurrence, and long-term intention to treat, disease-specific survival. From March 2004 to October 2014, RFA was performed as the initial stand-alone bridge therapy to LT for 121 patients (male:female = 83:38; mean age, 60.0 years) with 156 de-novo HCCs (mean size: 2.4 cm). Follow-up period from initial RFA ranged from 1.3 to 128.0 months (median: 42.9 months). We assessed the overall and tumor specific waiting list dropout rates, post-LT tumor recurrence, and the 10-year post-LT and intention-to-treat survival rates. Drop out from the waiting list due to tumor progression occurred in 7.4% of patients. HCC recurrence after LT occurred in 5.6% of patients. Post-LT overall survival (OS) and recurrence-free survival (RFS) rates at 5 and 10 years were 75.8% and 42.2%, and 71.1% and 39.6% respectively. Intention-to-treat OS, RFS, and disease-specific survival (DSS) rates for the entire study population at 5 and 10 years were 63.5% and 41.2%, 60.8% and 37.7%, and 89.5% and 89.5%, respectively. Conclusion: In the largest and longest intention-to-treat study to date of HCC treated by RFA as first line stand-alone bridge therapy to LT, long term overall and tumor specific survivals were excellent, with low dropout rate from tumor progression despite long wait list times, and sustained low tumor recurrence rate upon follow up post LT up to 10 years. This article is protected by copyright. All rights reserved.

StephenW

肝胆管恶性肿瘤
射频消融作为桥梁治疗肝移植的肝细胞癌：十年期治疗分析
作者

    在线接受手稿：2017年2月7日完整的出版历史
    DOI：10.1002 / hep.29098查看/保存引文
    引用：0文章

抽象

在长期（10年）的肝细胞癌（HCC）作为桥接治疗的常规肝移植（LT）患者的射频消融（RFA）研究中，我们评估RFA对等待名单辍学率， LT肿瘤复发，以及长期治疗意图，疾病特异性存活。从2004年3月至2014年10月，对156例新生HCC（平均大小：2.4cm）的121例患者（男性：女性= 83:38;平均年龄：60.0岁） ）。初始RFA的随访期为1.3〜128.0个月（中位数为42.9个月）。我们评估了整体和肿瘤特异性等待名单辍学率，LT后肿瘤复发，以及10年后LT和意向治疗存活率。 7.4％的患者由于肿瘤进展而从等待名单中退出。在5.6％的患者中发生LT后的HCC复发。 5年和10年的LT后总生存期（OS）和无复发生存期（RFS）分别为75.8％和42.2％，分别为71.1％和39.6％。整个研究人群在5和10年的意向治疗OS，RFS和疾病特异性存活（DSS）率分别为63.5％和41.2％，60.8％和37.7％，和89.5％和89.5％。结论：在迄今为止最大且最长的意向性治疗研究中，通过RFA治疗的作为LT的第一线单独桥治疗的长期总体和肿瘤特异性存活率是优异的，尽管长期的肿瘤进展的低脱落率等待列表时间，以及在LT后至10年的持续低肿瘤复发率。本文受版权保护。版权所有。